Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 28 entries
View as:

A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722

Phase: N/A Priority: Normal
NCT ID: NCT02346890 Org: User:
Start: 04/30/13 End: 04/30/13 Due: 04/30/14

D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02226783 Org: User:
Start: 03/31/13 End: 10/31/13 Due: 10/31/14

A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations

Phase: N/A Priority: Normal
NCT ID: NCT02249936 Org: User:
Start: 02/28/13 End: 02/28/13 Due: 02/28/14

An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)

Phase: N/A Priority: Normal
NCT ID: NCT02675998 Org: User:
Start: 01/31/16 End: 01/17/18 Due: 01/17/19

A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia

Phase: N/A Priority: Normal
NCT ID: NCT03018067 Org: User:
Start: 01/31/17 End: 05/31/17 Due: 05/31/18

AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study

Phase: N/A Priority: Normal
NCT ID: NCT02063386 Org: User:
Start: 04/30/14 End: 05/31/14 Due: 05/31/15

Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis

Phase: N/A Priority: Normal
NCT ID: NCT01764854 Org: User:
Start: 01/31/13 End: 10/31/13 Due: 10/31/14

Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia

Phase: N/A Priority: Normal
NCT ID: NCT04549597 Org: User:
Start: 11/20/20 End: 12/01/21 Due: 12/01/22

Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03824587 Org: User:
Start: 02/28/19 End: 07/17/19 Due: 07/17/20

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02819687 Org: User:
Start: 11/30/10 End: 08/31/11 Due: 08/31/12

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C

Phase: N/A Priority: Normal
NCT ID: NCT02621892 Org: User:
Start: 10/31/15 End: 04/30/17 Due: 04/30/18

A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Phase: N/A Priority: Normal
NCT ID: NCT01340053 Org: User:
Start: 05/31/11 End: 02/29/12 Due: 02/28/13

A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C

Phase: N/A Priority: Normal
NCT ID: NCT02727751 Org: User:
Start: 03/31/16 End: 10/31/17 Due: 10/31/18

To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02140268 Org: User:
Start: 05/31/14 End: 08/31/14 Due: 08/31/15

A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C

Phase: N/A Priority: Normal
NCT ID: NCT02686138 Org: User:
Start: 12/31/15 End: 10/31/17 Due: 10/31/18

A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

Phase: N/A Priority: Normal
NCT ID: NCT03988920 Org: User:
Start: 06/15/19 End: 07/31/21 Due: 07/31/22

An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females

Phase: N/A Priority: Normal
NCT ID: NCT06203444 Org: User:
Start: 11/27/23 End: 05/30/24 Due: 05/30/25

The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Phase: N/A Priority: Normal
NCT ID: NCT01923428 Org: User:
Start: 08/31/13 End: 10/31/14 Due: 10/31/15

To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02140281 Org: User:
Start: 05/31/14 End: 08/31/14 Due: 08/31/15

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

Phase: N/A Priority: Normal
NCT ID: NCT01847092 Org: User:
Start: 05/31/13 End: 04/30/15 Due: 04/30/16

Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02176252 Org: User:
Start: 07/31/13 End: 12/31/13 Due: 12/31/14

4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs

Phase: N/A Priority: Normal
NCT ID: NCT06553547 Org: User:
Start: 07/24/24 End: 06/30/26 Due: 06/30/27

Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02796131 Org: User:
Start: 07/31/11 End: 04/30/12 Due: 04/30/13

A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia

Phase: N/A Priority: Normal
NCT ID: NCT04780841 Org: User:
Start: 01/11/21 End: 03/03/22 Due: 03/03/23

A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis

Phase: N/A Priority: Normal
NCT ID: NCT03427125 Org: User:
Start: 01/08/18 End: 02/27/20 Due: 02/27/21